Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
BioVie Inc. BIVI
$7.63
-$0.16 (-2.05%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
282071310.00000000
-
week52high
14.38
-
week52low
1.33
-
Revenue
0
-
P/E TTM
-6
-
Beta
2.46851200
-
EPS
-1.38000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 февр 2023 г. в 21:00
Описание компании
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cantor Fitzgerald | Overweight | 22 июл 2022 г. | |
| EF Hutton | Buy | Buy | 17 мар 2022 г. |
| Oppenheimer | Outperform | 15 мар 2022 г. | |
| B. Riley Securities | Buy | Buy | 30 ноя 2021 г. |
| B. Riley FBR | Buy | 15 янв 2021 г. | |
| EF Hutton | Buy | Buy | 28 сент 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| ROGICH SIGMUND | A | 55000 | 55000 | 23 ноя 2022 г. |
| GORLIN STEVE | A | 84240 | 34240 | 23 ноя 2022 г. |
| Sherman Michael Edward | A | 75000 | 75000 | 23 ноя 2022 г. |
| MARKHAM PENELOPE | A | 50317 | 39624 | 23 ноя 2022 г. |
| DO CUONG V | A | 234848 | 79248 | 23 ноя 2022 г. |
| KIM JOANNE WENDY | A | 41624 | 39624 | 23 ноя 2022 г. |
| PEIZER TERREN S | A | 65000 | 65000 | 23 ноя 2022 г. |
| BERMAN RICHARD J | A | 45178 | 43578 | 23 ноя 2022 г. |
| Ahlem Clarence N. | A | 39624 | 39624 | 23 ноя 2022 г. |
| Palumbo Joseph M | A | 39624 | 39624 | 23 ноя 2022 г. |
Новостная лента
BioVie's degenerative dementia drug candidate to be presented at psychiatry conference
Proactive Investors
20 апр 2023 г. в 10:24
BioVie Inc (NASDAQ:BIVI) announced Thursday that a data abstract from its Phase 2 open-label trial of its degenerative dementia drug candidate has been accepted for presentation at the 78th Annual Scientific Convention of the Society of Biological Psychiatry. The event will be held April 27-29 in San Diego, with BioVie's presentation slated for April 28 at 5 pm PT.
BioVie To Present Data from NE3107 Phase 2 Open-Label Trial at Society of Biological Psychiatry Annual Meeting
GlobeNewsWire
20 апр 2023 г. в 08:30
CARSON CITY, Nev., April 20, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a data abstract from its Phase 2 open label trial evaluating NE7107 in degenerative dementias has been accepted for presentation at the 78th Annual Scientific Convention of the Society of Biological Psychiatry , to be held in San Diego, CA April 27-29, 2023.
BioVie to present Phase 2 trial data abstracts at 2023 American Academy of Neurology Annual Meeting
Proactive Investors
17 апр 2023 г. в 12:01
BioVie announced that data abstracts from its Phase 2 trials evaluating NE3107 in degenerative dementias and Parkinson's disease will be presented at the 2023 American Academy of Neurology Annual Meeting, being held virtually and in Boston, Massachusetts from April 22 to 27. The company's drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB which lead to neuroinflammation and insulin resistance in neurodegenerative disease without impacting their homeostatic functions such as insulin signalling and neuron growth and survival, according to BioVie.
BioVie: Update On Alzheimer's And Parkinson's Programs, And Focus On Its Treatment For Refractory Ascites
Seeking Alpha
15 мар 2023 г. в 01:06
BioVie's stock has moved up considerably over the past 9 months in light of promising Alzheimer's data. BioVie Day and full Phase 2 Parkinson's trial results are scheduled for this month.
BioVie pauses patient enrollment in BIV201's Phase 2b trial for ascites after positive data; initiates FDA discussions on pivotal Phase 3 trial
Proactive Investors
13 мар 2023 г. в 09:23
BioVie Inc (NASDAQ:BIVI) revealed that it had paused patient enrollment in its Phase 2b clinical trial evaluating BIV201 for the treatment of refractory ascites after seeing encouraging data from the first 15 patients in the study. Ascites is a common complication of advanced liver cirrhosis involving the large accumulation of fluid in the abdomen, often exceeding 5 liters, due to liver and kidney dysfunction.